In a small study, 6 DLBCL patients received the anti-PD-L1 Ab durvalumab 21–28 days after CAR T cells infusion, and 9 patients were treated with durvalumab the day before infusion [67]. The gene discussed is CD274; the disease is diffuse large B-cell lymphoma.